Blocking plasma factors of migration inhibition factor production in patients with cervical carcinoma. A possible role in vivo.
The blocking activity was studied of plasma from patients with cervical carcinoma in a model of migration inhibition factor (MIF) production by normal human leukocytes. At the same time, the patients' in vivo (intradermal reactivity) and in vitro (MIF assay) responses were studied with two common antigens (streptokinase-streptodornase and purified protein derivative). The plasma of 15 of 27 patients with carcinoma was capable of blocking the MIF test of human normal leukocytes. Twelve of 15 patients with blocking factor in their plasma had no or only a slight in vivo response, although they had a good in vitor response. Two patients had blocking factor without any in vivo or in vitro response. Six patients who had in vitro responses and slight or no in vivo responses had no plasma blocking activity. Three patients had neither in vivo nor in vitro responses and lacked blocking activity in their plasma.
D002464:Cell Migration Inhibition; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy; D008263:Macrophage Migration-Inhibitory Factors / Q000032:analysis; D012882:Skin Tests; D002583:Uterine Cervical Neoplasms / Q000276:immunology*
D008263:Macrophage Migration-Inhibitory Factors